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Beta-catenin is involved in both cell–cell adhesion and in transcriptional regulation by the Wingless/Wnt signalling pathway.
Alterations of components of this pathway have been suggested to play a central role in tumorigenesis. The present study
investigated, by immunohistochemistry and immunoblotting, the protein expression and localisation of b-catenin, adenomatous
polyposis coli (APC), glycogen synthase kinase 3b (GSK3b) and lymphocyte enhancer factor-1 (Lef-1) in normal human ovaries and in
epithelial ovarian tumours in vivo and in vitro. Immortalised human ovarian surface epithelium and ovarian cancer cell cells (OVCAR-3)
expressed b-catenin, APC, GSK3b and Lef-1. Nuclear staining of b-catenin and Lef-1 were demonstrated only in OVCAR-3 cells.
There were significant increases of b-catenin and GSK3b, while APC was reduced in ovarian cancer compared to the normal ovary.
Beta-catenin and Lef-1 were coimmunoprecipitated in ovarian tumours, but not in the normal ovary. Nuclear localisation of b-catenin
or Lef-1 could not be demonstrated in the normal ovary or in the ovarian tumours. The absence of nuclear localisation of b-catenin
could be due to an increased binding to the cadherin–a-catenin cell adhesion complex. In fact, we have earlier reported an increased
expression of E-cadherin in ovarian adenocarcinomas. In summary, this study demonstrates an increase in the expression of
components of the Wingless/Wnt pathway in malignant ovarian tumours. The increase suggests a role for this signalling pathway in
cell transformation and in tumour progression. However, it remains to be demonstrated whether it is an increased participation of
b-catenin in transcriptional regulation, or in the stabilisation of cellular integrity, or both, that is the crucial event in ovarian
tumorigenesis.
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The cytoplasmic protein b-catenin, initially discovered as a
component of cell–cell adhesive junctions, has also been demon-
strated to be a critical downstream mediator of Wnt-signalling
(Giarre ´ et al, 1998). Beta-catenin is phosphorylated by glycogen
synthase kinase 3b (GSK3b), in connection with the tumour-
suppressor gene product adenomatous polyposis coli (APC) and
Axin. The formation of this complex depends on the GSK3b
phosphorylation status. In the normal cell, degradation of
b-catenin through the ubiquitin pathway is facilitated by
phosphorylation (BenZeev and Geiger, 1998). Mutational changes
to the complex will lead to an increased free pool of b-catenin in
the cytoplasm. Apart from being important for cell–cell adhesion,
b-catenin also binds to the transcription factor T-cell factor/
lymphocyte enhancer factor (Tcf/Lef) either in the cytoplasm or in
the nucleus. This is followed by transcriptional activation of target
genes, that is, c-myc, E-cadherin and cyclin D1 (reviewed by Roose
and Clevers, 1999). In adherens junctions, b-catenin binds directly
to the cytoplasmic tail of cadherins and will thereby stabilise cell–
cell adhesion. The regulation of this dual function of b-catenin is
not clear (Giarre ´ et al, 1998).
The majority of ovarian tumours are epithelial-derived adeno-
mas or adenocarcinomas. They are believed to arise from inclusion
cysts situated in the ovarian stroma and will typically grow in
cystic formations or solid formations (Scully, 1995). The
adenocarcinomas invade the nearby pelvic surroundings and later
the abdomen by direct growth or via ascites fluid. Haematogenous
spread with peripheral metastases, for example, to the liver and
lung, are rare.
Cell–cell adhesion has been implicated to be of great
importance for the invasive capacity of most tumour types. The
downregulation of cadherins or dysfunction of the cadherin–
catenin complex has been noted in different types of tumours. In
the human ovary, neuronal (N) cadherin, but not epithelial (E)
cadherin, is expressed in the normal ovarian surface epithelium
(OSE) (Sundfeldt et al, 1997; Auersperg et al, 2001). However, E-
cadherin is upregulated in inclusion cysts of the normal ovary and
in ovarian tumours with invasive capacity (Sundfeldt et al, 1997;
Auersperg et al, 2001). At the protein level, both a- and b-catenin
are expressed in normal OSE and invasive ovarian tumours
(Auersperg et al, 2001). Mutations of the b-catenin gene at the
binding site for GSK3b was demonstrated in 16–30% of the
endometrioid type of ovarian adenocarcinomas, but not in other Revised 15 May 2003; accepted 8 July 2003
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ytypes of ovarian tumours (Gamallo et al, 1999; Wright et al, 1999).
GSK3a and GSK3b mRNAs have been described in normal human
ovaries (Lau et al, 1999). The expression of GSK3 has, to our
knowledge, not been investigated in ovarian tumours previously.
Mutations of APC, considered to be a tumour suppressor,
predispose for both sporadic and inherited colon cancers. It is
not known whether APC is mutated in ovarian tumours or not.
However, the expression of APC has been demonstrated in normal
OSE (Midgley et al, 1997), with less staining in 72 out of 113 serous
ovarian carcinoma (Karbova et al, 2002) and in a large variety of
other tumours (Smith et al, 1993).
The aim of this study was to analyse components of the Wnt-
signalling pathway in normal human ovaries and in ovarian
tumours of epithelial origin. Cell-specific protein expression and
protein–protein interactions were investigated in normal ovaries,
benign and malignant tumours.
MATERIALS AND METHODS
Human tissue
Biopsies from normal ovaries and epithelial ovarian tumours were
obtained from patients undergoing laparotomy (approved by the
Ethics Committee, Go ¨teborg University, Sweden). Tissues were
immediately washed in ice-cold 0.9% NaCl, snap frozen in liquid
nitrogen and stored at  701C until analysis. Ovarian tumours were
classified according to surgical staging. All samples were examined
by two independent and experienced gynaecological pathologists
for histological diagnosis and grade (Table 1). An SV-40
immortalised ovarian surface epithelial (IOSE) cell line (a gift
from Professor Auersperg, University of British Columbia,
Canada) and the cancer cell line, NIH-OVCAR-3 (no. HTB161,
ATCC, Rockville, MD, USA) were used. One colorectal cancer
(CRC), Dukes stage A and one normal colorectal biopsy from the
same patient was used as control for the anti-APC antibody.
Immunoblotting
Soluble tissue and cells were prepared by homogenisation in a PE-
buffer with proteinase inhibitors, analysed for protein content by
the method of Lowry and stored at  701C as previously described
(Sundfeldt et al, 1999). Briefly, 35mg of total protein was diluted in
a sodium dodecyl suplhate (SDS)-sample buffer and heated before
loading on a 1D SDS-polyacrylamide gel (8% Tris-Glycine) or
NuPage gel (10%) (NOVEX, San Diego, CA, USA). Proteins were
transferred onto a polyvinyldifluoride (PVDF) membrane (Amer-
sham, Buckinghamshire, UK) using a blotting system (NOVEX).
The membrane was then incubated with antibodies against
b-catenin (monoclonal, 1:1000), GSK3b, (monoclonal, 1:500)
(Transduction Laboratories, Nottingham, UK), a-catenin (mono-
clonal, 1:1000; Alexis, Lausen, Switzerland) APC-COOH terminus
or APC-NH2-terminus (polyclonal, 1:500; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), Tcf-Lef (polyclonal) and Lef-1
(monoclonal, 1:500; Kamiya Biomedical Company, Seattle, WA,
USA) or Lef-1 antiserum (1:10000) (Carlsson et al, 1993).
Prestained standards (SeeBlue; NOVEX) were used as weight
markers. Immunoreactive proteins were visualised by chemilumi-
nescence using alkaline phosphatase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology) and CDP-star (Tropix, Bedford,
MA, USA) as substrate.
Densitometric scanning
Semiquantitative measurements of proteins from the immunoblots
were made by densitometry (Fluor-S
TM Multimager, Quantity One
ver. 4.1.0., BioRad, Hercules, CA, USA). The optical density (OD)
of each band was measured. For quantification, a reference sample,
same on each blot, was included. The standard was set to 100%.
The signal from each band was then correlated to the standard and
this relative number was used in the statistical analysis.
Immunohistochemistry (IHC)
Fresh frozen tissues were cryosectioned and fixed in cold acetone
for 10min, air dried and stored at  201C as previously described
(Sundfeldt et al, 1999). Briefly, slides were blocked with 5% nonfat
milk (NFM) before the addition of primary antibodies to b-catenin
(1:100), Lef-1 (1:100), Lef-1 antiserum (1:100), GSK3b (1:50),
APC-COOH and APC-NH2-terminus (1:100) and incubated over-
night. Bound antibodies were visualised by biotinylated secondary
horse anti-mouse or goat anti-rabbit antibodies (1:200; Vector,
Burlingham, CA, USA) and Streptavidin-FITC (1:200; Amersham,
Buckinghamshire, UK). In control sections, which showed
negligible signals, the first antibody was replaced by normal
mouse IgG (Jackson Immuno Research, West Grove, PN, USA) or
5% NFM (Figure 4G and I). Sections were photographed with a
Nikon microphot FX fluorescence microscope. To verify the
epithelial origin of cells, all samples were stained with anti-keratin
AE1/AE3 monoclonal antibody (1:40) (cat. no. 1124161, Boehrin-
ger Mannheim, Germany) (Figure 4H).
Immunoprecipitation
Immunoprecipitations were performed with the Seize-It Mamma-
lian Primary Antibody Precipitation kit (Pierce, Rockford, IL,
USA) and Catch-and-Release (Upstate Biotechnology, Charlottes-
ville, VA, USA) according to the protocols provided by each
manufacturer, with modifications. Briefly, a soluble lysate of an
ovarian serous adenocarcinoma, poorly differentiated, stage III,
was prepared as described above with the exception of the
homogenisation buffers that were provided with the kits. The
lysates (1mg of total protein per sample) were incubated with the
primary antibody overnight at 41C on a rotating platform. The
eluted fractions were concentrated by ethanol precipitation
Table 1 Histological description
Stage













High diff 2 1 1
High/moderately diff 2 2
Moderately diff 6 1 5
Moderately/poor diff 6 2 4
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y(Current Protocols, Wiley & Sons) and vacuum-dried. The pellets
were dissolved in an SDS-sample buffer. Separation by SDS–PAGE
and immunodetection was performed as described above.
Statistics
The nonparametric Kruskal–Wallis test for comparing groups was
followed by the post hoc Wilcoxon rank-sum test and used in the
analysis of immunoblotting data obtained by the densitometric
scanning of membranes. A P-value less than 0.05 was considered to
be significant. Values are given as mean7s.e.m.
RESULTS
Intracellular localisation of b-catenin, Lef-1, GSK3b and
APC in IOSE and OVCAR-3
The normal IOSE cells demonstrated staining of b-catenin at the
cell borders (single arrow and black stars (Figure 1A). In OVCAR-
3, b-catenin was localised to the nucleus of some cell clusters
(double arrows, Figure 1B) in addition to the general staining of
the cell membranes (single arrow and black star, Figure 1B). Lef-1
was present in the nucleus with a punctuated staining pattern
(double arrows; Figure 1C). However, cytoplasmic staining was
more prominent for Lef-1, APC and GSK3b in OVCAR-3 cells
(Figure 1D, arrows; not indicated in E). GSK3b and APC was
concentrated to the cell borders of some OVCAR-3 cells (Figure 1D,
black star and Figure 1F, arrows). Two antibodies against APC
were used (APC-COOH and APC-NH2) in the analyses and anti-
APC NH2-terminus was found to be the most reliable for both IHC
and immunoblots. This antibody recognizes full-length APC and
truncated APC (Reinacher-Schick and Gumbiner, 2001).
Increased expression of b-catenin and GSK3b in ovarian
adenocarcinomas
The expression of b-catenin and GSK3b was analysed by
immunoblotting in normal ovaries, benign adenomas, borderline
tumours and adenocarcinomas. Statistical analysis revealed
significant increases of b-catenin (Po0.01) and GSK3b
(Po0.001) in the group of ovarian adenocarcinomas (AC) as
compared to the group of normal ovaries (N) and benign
adenomas/borderline tumours (BB) (Figure 2A and B).
Lef-1 was expressed in all samples analysed. Even though higher
levels of Lef-1 were demonstrated in malignant ovarian tumours,
this increase was not significant compared to normal and benign
ovarian tumours (Figure 2C). The estimated molecular weights of
the proteins expressed in these tumours were as expected: 92kDa
for b-catenin, 46–48kDa for GSK3b and approximately 55–60kDa
for Lef-1.
Expression of APC in normal ovaries and ovarian tumours
APC was expressed in seven out of 12 ovarian samples examined.
As a control of APC expression, a normal colon sample and a
colorectal carcinoma (CRC; Duke A) from the same patient was
included. The normal colon sample, normal ovaries, benign
adenomas and borderline-type tumours exhibited higher expres-
sion of a band at the expected molecular weight (312kDa)
compared to the adenocarcinomas, OVCAR-3 cells and CRC
(Figure 3). Three-fourths of the ovarian carcinomas, half of the
borderline tumours, OVCAR-3 cells and the CRC had none or very
low expression at 312kDa. Bands of unknown importance that
could represent truncated APC gene products were also found at
approximately 180 and 110kDa.
Cell-specific localisation of b-catenin and Lef-1 in the
normal ovary and ovarian tumours
Normal ovaries from eight patients were stained for b-catenin. In
OSE and in epithelial cells lining inclusion cysts, b-catenin was
localised at the cell borders (Figure 4A and B). Two benign
adenomas, four borderline tumours and 18 adenocarcinomas
(serous, mucinous and undifferentiated) of different stages and
grades exhibited strong and specific b-catenin staining in the
epithelial cells of the tumours (Figure 4C–F). Staining for b-
catenin was mainly confined to the cell borders in benign
adenomas, borderline and high grade tumours. In one metastasis
from a moderately differentiated serous adenocarcinoma and one
undifferentiated carcinoma, more diffuse or punctuated staining of
the cytoplasmic compartment was present (Figure 4D and F).
There was, in contrast to the OVCAR-3 cells, no staining of the
nucleus in the tumour cells.
Lef-1 was localised to the OSE cells in two normal ovaries.
Staining of Lef-1 was confined to the cytoplasm and cell borders of
these cells and in the epithelial-derived tumour cells of two benign
adenomas, two borderline tumours. Lef-1 dominated in the
cytoplasm of the more malignant tumour cells including three
serous ovarian adenocarcinomas (stage III) and one undifferen-
tiated adenocarcinoma (stage III) (Figure 5A–D). The dotted
staining of the nucleus found in OVCAR-3 cells could not be seen
in the tumour biopsies.
Figure 1 Immunohistochemistry analysis of (A) normal IOSE, (B–E)
ovarian cancer cell line OVCAR-3, stained with antibodies directed
towards; (A, B) b-catenin, (C) Lef-1, (D) GSK3b,( E) APC-COOH
terminus and (F) APC-NH2 terminus. See text for explanation of arrows
and stars. Bar¼50mm.
Wnt-signalling pathway in ovarian tumours
K Rask et al
1300





























yProtein–protein interaction between b-catenin and Lef-1
Immunoprecipitation was performed in order to detect a
physical interaction between b-catenin, a-catenin and Lef-1
(Figure 6). A serous adenocarcinoma was immunoprecipitated
with b-catenin, Lef-1, Tcf/Lef, a-catenin or Axin and blotted for the
detection of a-catenin, b-catenin or Lef-1 (Figure 6). The same
sample was also subjected to immunoblotting without immuno-
precipitation (Figure 6, lane 1) to serve as a control for
immunodetection. The immunoprecipitate with b-catenin con-
tained one band for Lef-1 with the expected molecular weight of
approximately 60kDa (Figure 6, lane 2). This band was also
present in the homogenate not subjected to immunoprecipitation
(Figure 6, lane 1). In line with this, b-catenin/Lef-1 was co-
precipitated in OVCAR-3 cells, but not in a normal ovary (data not
shown).
In the b-catenin immunoprecipitates, expression of GSK3b or
APC was not detected (data not shown). However, silver staining of
the gel for the immunoprecipitates after transfer revealed a band
with a molecular weight of approximately 300kDa in the
adenocarcinoma, suggesting APC as an interacting partner with
b-catenin in this tumour, in addition to Lef-1 (data not shown). In
addition, b-catenin was also immunoprecipitated with a-catenin
(Mr¼102kDa; Figure 6, lane 2). The reverse was also demon-
strated (Figure 6, lane 5). This emphasises the dual role for b-
catenin in these cells.
The immunoprecipitation with Lef-1 in the ovarian tumour
sample also contained a band for b-catenin at the expected size of
92kDa (lane 3). The b-catenin band was also present in
immunoprecipitates with Tcf/Lef and Axin (lanes 4 and 6).
DISCUSSION
In recent years, it has become clear that b-catenin, earlier only
known as an important protein in cadherin-mediated cell–cell
adhesion, also plays a crucial role in Wnt-signalling. In the normal
cell, binding of b-catenin to APC, GSK3b and Axin will lead to
degradation of b-catenin through the ubiquitin–proteasome
pathway. The importance of b-catenin in the Wnt-pathway was
originally described in colon and melanoma cells (Morin et al,
1997; Rubinfeld et al, 1997). We hypothesised that the normal OSE
cells also express proteins in the Wnt-signalling pathway and that
their deregulation could be of importance for ovarian tumorigen-
esis.
Ovarian surface epithelium is commonly believed to be the
origin for ovarian adenocarcinomas, which arise in inclusion cysts
lined with OSE (Scully, 1995). In our study, normal OSE lining the
surface of the ovary and the inclusion cysts expressed b-catenin,










































































































































































































Figure 2 Beta-catenin, GSK3b and Lef-1 protein expression presented
with histograms and representative immunoblots. The semiquantitative
measurements are expressed as mean7s.e.m. and as percentage changes
from an internal reference sample, the same for each gel. Kruskal–Wallis,
followed by the Wilcoxon rank-sum test as post hoc test, was used for
statistical analysis of the data obtained by densitometric scanning. a –
Po0.05 vs normal (N) b – Po0.05 vs benign/borderline (BB). (A, B)
O¼OVCAR-3 cells, N¼normal ovary (n¼2), BB¼benign serous
adenoma/adenofibroma and borderline type tumour (n¼8),
AC¼adenocarcinoma; highly, moderately and poorly differentiated
(n¼21), M¼peritoneal metastasis (n¼4). An undifferentiated carcinoma
(not included in the histogram) was used as an internal reference sample.
(A) Expression of b-catenin. (B) Expression of GSK3b.( C) Expression of
Lef-1. N¼normal ovary (n¼7), BB¼benign serous adenoma/adenofi-
broma and borderline-type tumour (n¼9), AC¼adenocarcinoma; highly,
moderately and poorly differentiated (n¼20). One of the adenocarcino-
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Figure 3 Adenomatous polyposis coli protein expression in ovarian
tissue samples presented with a representative immunoblot: (1) colon
tumour, Duke A, (2) normal colon mucosa from the patient with a Duke A
tumour, (3) OVCAR-3 cells, (4–6) normal ovary, (7, 8) benign adenoma,
(9, 10) borderline-type tumour, (11–14) serous adenocarcinoma. The
standard marker is indicated at 100–150–250kDa. Adenomatous
polyposis coli indicated at approximately 312kDa.
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yepithelial cells was demonstrated by immunohistochemistry.
Others, as well as the results of this study, have revealed that b-
catenin is localised at the cell borders and not in the nucleus of
normal OSE or OSE lining the inclusion cysts (Davies et al, 1998).
However, nuclear b-catenin has been described in normal cells of
other organs such as the endometrium of the uterus (Nei et al,
1999). Mutations in the b-catenin gene are infrequent in ovarian
carcinoma and interestingly only described in the endometrioid
type of epithelial ovarian tumours (Palacios and Gamallo, 1998;
Wright et al, 1999). Allelic imbalance has not been found in the
b-catenin gene in ovarian cancers (Nollet et al, 1997), but
histological grade was not stated in their study. The Tcf-Lef
family, members of the HMG-box transcription factors, are
expressed in the normal epithelium from different organs,
localised to the nucleus or the cytoplasm (Barker et al, 1999). To
our knowledge, Lef or Tcf has not been described previously in the
ovary. We could neither detect nuclear staining in normal OSE nor
co-precipitate b-catenin/Lef in normal ovarian tissue. We therefore
conclude that a complex of b-catenin/Lef, for transcriptional
regulation, is less likely to be formed in normal OSE.
The function for GSK3b and APC in the human ovary is not
known. However, as for other epithelial cells, it could be speculated
that GSK3b and APC regulate the free pool of b-catenin in normal
ovarian cells. Normal APC function seems to be critical for the
colorectal mucosal epithelium, since APC mutations are often
Figure 4 Staining with anti-b-catenin in normal human ovaries and in
ovarian tumours. Immunohistochemical analysis of (A) normal ovary with a
stained surface epithelium, (B) inclusion cysts located in the normal ovarian
stroma lined with epithelial cells, (C) borderline-type tumour, (D)
peritoneal metastasis from a moderately/poorly differentiated adenocarci-
noma, (E) adenocarcinoma moderately/poorly differentiated; stage III, (F)
undifferentiated carcinoma, stage III. (G, H) Sections of A: (G) negative
control with IgG as primary antibody, (H) positive control with cytokeratin
as the primary antibody. (I) Section of F: negative control with 5% nonfat
milk as the primary antibody. Bar¼50mm.
Figure 5 Staining with anti-Lef-1 in a normal human ovary and in ovarian
tumours. Immunohistochemical analysis of (A) normal ovary with surface
epithelium, (B) benign serous cyst adenoma, (C) borderline-type tumour,
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Figure 6 Immunoprecipitation (IP) of extracts from a serous adeno-
carcinoma (poorly differentiated, stage III). Lane (1) tissue extract, not
subjected to IP. Lanes 2–6, IP with the following antibodies; (2) b-catenin,
(3) Lef-1, (4) Tcf/Lef, (5) a-catenin, (6) axin. The precipitates were
immunoblotted with a-catenin (upper left section), b-catenin (upper right
section), and Lef-1 (lower section).
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yfound in the earliest stages of colorectal tumorigenesis. The APC
protein has been demonstrated in several subcellular compart-
ments including the cytoplasm, nucleus and adhesive cadherin–
catenin junctions (Rosin-Arbesfeld et al, 2000). In the current
study, cytoplasmic and cell border staining of the overlying
epithelium (OSE) was present, while nuclear staining was absent.
Nuclear APC staining has been described in the uterus using the
same antibody as in this study (Nei et al, 1999). We believe that
APC was not truncated in the normal ovary or in the normal colon
sample since the immunoblot demonstrated a band at the expected
size of 312kDa (Smith et al, 1993). GSK3 is a serine/threonine
specific kinase that was initially shown to phosphorylate and
inactivate glycogen synthase (reviewed by Frame and Cohen,
2001). Other targets for phosphorylation have now emerged,
that is, b-catenin. We have localised GSK3b to the cytoplasm
and the cell borders of OSE lining the ovary and inclusion cysts.
The expression of both GSK3a and GSK3b were previously
described in the normal ovary (Lau et al, 1999) at the mRNA
and protein level.
In the present study, we found a significant increase of b-catenin
and GSK3b in the adenocarcinomas as compared to normal
ovarian tissue and benign adenomas. Adenomatous polyposis coli
expression was decreased or absent in ovarian adenocarcinomas,
while Lef-1 was constantly expressed in all the tissues analysed.
This indicates a possible role for the Wnt-pathway in ovarian
tumour cells. Several members of the Tcf-Lef family are expressed
in colorectal cancer cells and malignant mammary epithelium
(Van de Wetering et al, 1996). Nuclear staining for b-catenin and
Lef-1, indicating dysfunction in normal Wnt-signalling, was found
in the OVCAR-3 cells but not in ovarian tumour biopsies. Nuclear
b-catenin was recently noted in 12 out of 96 serous adenocarci-
nomas (Lee et al, 2003). This could explain why Lef-1, in our study,
was found to co-precipitate with b-catenin in an ovarian serous
adenocarcinoma and in the OVCAR-3 cell line. Constitutive b-
catenin/Lef-1-mediated transcriptional activity has been detected
in four out of 19 investigated ovarian cancer cell lines (Furlong and
Morin, 2000).
Beta-catenin has additional functions in the cell since it also
binds to the cadherin cell–cell adhesion complex. In fact, both N-
and E-cadherin can reduce or block the transcriptional activity of
b-catenin/Lef1, relocate b-catenin to the cell border and inhibit the
degradation of b-catenin (Sadot et al, 1998). We and others have
earlier demonstrated that E-cadherin is induced during the
progression of ovarian epithelial tumours (Sundfeldt et al, 1997;
Auersperg et al, 2001). The elevated expression of E-cadherin in
ovarian cancer could increase binding of b-catenin to the plasma
membrane. This would then reduce the free pool of cytoplasmic b-
catenin and inhibit nuclear translocation, reflected by the absence
of nuclear b-catenin in ovarian tumours in this study. In fact, the
absence of E-cadherin can lead to an accumulation of free b-
catenin and increased transactivation, which can be competed out
by transient transfections with E-cadherin (Orsulic et al, 1999).
Beta-catenin was recently found to be involved in apoptosis
(Herren et al, 1998). Their finding that caspases have the capacity
to cleave b-catenin proteolytically at the N- and C-terminal, which
will reduce a-catenin binding, release actin filaments and reduce
cell–cell interaction, indicates that b-catenin has an important role
at a late stage of apoptosis. Studies on oral squamous cell
carcinoma cells also indicate that cadherin-mediated adhesion
promotes anchorage-independent growth and suppresses apopto-
sis (Kantak and Kramer, 1998). A functionally intact cadherin-b-a-
catenin complex in ovarian cancer could make the cancer cells less
susceptible to apoptosis and thereby favour growth.
In patients linked to familial adenomatous polyposis, trunca-
tions of or mutations in the APC gene are believed to enhance the
progression of colorectal or gastric tumours, presumably through
stabilisation of b-catenin in the cytoplasm (Rubinfeld et al, 1996).
In the present study, APC expression was demonstrated in normal
ovaries and benign tumours, but was low or absent in malignant
ovarian tumours. Genetic changes in the APC gene in ovarian
tumours have not been described. With the anti-APC NH2-
terminus antibody, low or absent levels of full-length APC protein
were noted in adenocarcinomas and OVCAR-3 cells even though
staining of tumour cells was positive. A lower band that might
represent a truncated form of APC was demonstrated in these
samples. It has been suggested that the NH2-terminal fragment of
APC is sufficient to localise APC to the apical membranes
together with GSK3b, Axin, dishevelled and b-catenin forming
a high molecular weight complex that catalyses the degradation
of b-catenin (Reinacher-Schick and Gumbiner, 2001). The
recently found APC-like gene, APC2, which presented with
allelic imbalance in 19 out of 20 ovarian cancers (Jarrett
et al, 2001), is also noteworthy. It will be very interesting to follow
up whether this protein has an impact on Wnt-signalling in the
ovary.
Mutational changes of members of the APC/Axin/b-catenin
complex results in accumulation of cytoplasmic b-catenin and
nuclear localisation. Nuclear transcriptional activation by b-
catenin/Tcf-Lef of specific targeted genes, that is, c-Myc and
cyclin D, which are upregulated in ovarian tumour, could be
important steps in tumour initiation and/or progression (BenZeev
and Geiger, 1998). The possible up- or downregulation of
suggested targeted genes, however, has not been assessed in this
study.
In conclusion, this study demonstrates a significant change in
the expression of some components in the Wnt/Wingless-
signalling pathway in ovarian epithelial tumours. This could
indicate dysfunction of the APC–b-catenin–GSK3b complex.
Lef-1/b-catenin precipitates were also found in malignant
ovarian cancer, but without concomitant staining in the nucleus
of the tumour cells. The proteosomal degradation of b-catenin
could still be active or b-catenin might be focused at the cell–cell
junctions via the high E-cadherin expression in ovarian
tumours, which in turn could favour tumour growth. In contrast
to other tumours, the transcriptional activity of Lef-1/b-catenin
might play a minor role in ovarian epithelial tumours. Further
studies with an in vitro approach need to be conducted to elucidate
whether the transcriptional activity of b-catenin–Lef-1 and/or
increased cell-junction stability is of importance in ovarian
tumorigenesis.
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